After a decisive victory in Illinois, it's about time for Republicans and the other Republican Presidential hopefuls to come to close up shop and realize that Mitt is going to be their man come November.
Although Rick Santorum will use the fact that he got outspent "21-1" as the excuse for racking up another "L" in the loss column, it's also a big reason as to why there's little chance he'll make up ground in any states following Illinois.
What's done is done, time to "man up" and bow out gracefully instead of making silly attempts to try and evoke a comparison to Reagan with quotes like the one where he told his supporters to "saddle up like Reagan did in the cowboy movies."
Come on now, if cowboy movies is all the campaign has left, it's time to ride off into the sunset.
With another Republican showdown taking place on Tuesday, the media gave little notice to the deteriorating situation in Syria, which grabbed headlines over the weekend when Damascus started reminding many of Sarajevo.
The talk now revolves around potential United Nations "safe havens" and "corridors" that can be used to bring humanitarian supplies to those who have been displaced or injured by the fighting. For those thinking that this might be a good idea, remember Srebrenica?
That was a UN "safe haven," too, and anyone using the "corridors" for peaceful purposes just become hostage targets for the Assad crew to be used as pawns in any international negotiations.
The opposition wants weapons. If the International Community wants to help, like they did in Libya, then they'll either have to do their business or get off the pot, because cursory measures like "safe havens" will just prolong the inevitable.
Those who might have thought that Tim Tebow is getting a raw deal with Peyton Manning showing up in Denver need to take a look at Mark Sanchez and the New York Jets. Reports have it that with the Jets losing out in the Manning sweapstakes, team brass is looking at trading for Tebow.
It's one thing to try and light some fire under Sanchez by toying with the Manning idea, but Tebow? Are you trying to motivate the guy - make him feel like his starting job is on the line - or are you just downright trying to insult him? Bad move by the Jets letting that story get out, as I'm sure Sanchez got nothing more than a chuckle out of that one.
Speaking of bad moves, the Wilpons are back at spring training with grins that expand from ear to ear - and they're not smiling because they like the chances of the New York Mets making the Wild Card this year.
Maybe they're smiling because the Curse of the Wilpons has now extended to Andres Torres, the speedy center fielder that was to replace Jose Reyes at the top of the lineup, who went down on Tuesday with a calf injury.
Nope, those guys are smiling because the headlines on Tuesday informed fans that even though a hundred million dollars or so opened up as a result of the settled Maddof lawsuit, no one should count on seeing any new talent arrive at Citi this year.
During the depths of the economic crisis, when Citi Group had to be bailed out by the governments, there was outrage over the amount of cash that Citi was shelling out to the Mets for naming rights for Citi Field. You have to wonder now how much Citi wishes that it had been forced to revoke that deal. You'd think that somewhere in the contract the Mets would be required to field a team.
Other notable headlines from Tuesday, in case you missed these - Jersey Shore's "The Situation" goes to rehab while Snooki boozes it up pregnant - gotta love American pop culture.
And here's one from Richard Gere, who says that the movie that put him on the map, Pretty Woman, was "silly." Coincidently enough, Gere is trying to make headlines just when he's promoting his new movie, in which he plays a guy from - you guessed it - Wall Street.
The tales of fading Hollywood stars never get old.
Luckily, there was a whole lot more going on in the markets on Tuesday...
Amarain Corporation (AMRN): Shares of Amarin Corporation (AMRN) were running big on Tuesday, as even bigger volume led to a 12% price spike on news that the US Patent and Trademark (USPTO) had finally awarded the company its elusive patent for AMR-101, a treatment for high trigylcerides that was very successful in late stage trials.
AMR-101 is currently before the FDA for approval, and the general market sentiment has it that an approval is likely.
Investors had been predicting news for the better part of a week after shares started rallying from below the eight dollar mark to their current trading levels. With the patent news now out of the way, speculation will be thrown towards the possibility of Amarin landing a big commercial partner.
Such speculation fueled a run to nearly twenty dollars last year, and it's almost a near-certainty that partnership or buyout rumors will surround this company at some point again, especially with the FDA decision so close.
That's just the nature of the beast in the biotech and health care sectors where having an already-established player with an existing sales and marketing force on your side is almost a necessity in order to guarantee a successful commercial launch of a new product.
Amarin shares may quickly return to previously-traded levels if the news plays out positive, and it's a hot stock to watch right now.
Celsius Holdings (CELH): Celsius Holdings (CELH) has been another stock to watch lately, as a stark increase in trading volume last week set off some speculative bells that a price move might be next.
Volume continued to roll in during the opening days of the new trading week and a strong push on Tuesday resulted in nearly 70,000 shares trading hands and a price close 50% higher than the open. Each day that the trading volume remains inflated is a positive sign that a rebound could be coming for this company and its stock, and investors are safe to assume that future announcements related to the new PR push could be forthcoming.
"We are excited to implement a consumer focused campaign, to reach trendsetters, celebrities and heighten awareness of the Celsius brand."
With the share price already responding and with a new PR push in store, it could again be exciting times ahead for Celsius Holdings and its shareholders.
Other noteworthy stories:
Ampio Pharmaceuticals (AMPE): Shares of Ampio Pharmaceuticals (AMPE)continued to move on high volume early Tuesday before tapering off to close the day below the four dollar mark, still significantly higher than where they traded before the recent announcement of positive trial news.
Ampio has numerous catalysts still pending this year relating to the initiation of pivotal trials that will be necessary to garner FDA approvals for its products, and the early-year interest could grow as these stories develop.
Cel-Sci Corp (CVM): Cel-Sci Corp (CVM) has quietly been putting together a price run of its own, with another eight percent gain on big volume being recognized on Tuesday.
Cel-Sci is working with its partners, Teva (TEVA) and Orient Europharma, to bring the immunotherapeutic head and neck cancer treatment, Multikine, to market. An international Phase III trial is currently underway and it's expected that the trial, with a planned enrollment of over 800 subjects, will be the largest ever for head and neck cancer.
The company recently announced the full repayment of a debenture that had resulted from a settlement of litigation and freed some of the dead weight that was holding the stock down for months.
With volume picking up along with the share price, CVM could again be a story to watch, especially as the Phase III trial picks up momentum. Although partners have been announced for some international regions, it's possible Cel-Sci could seek a US Multikine partner as well.
Multikine's potential should not go unnoticed, given that it is being tested as a first-line treatment at a time when cancer immunotherapies are consistently gaining acceptance in the field of medicine.
NovaBay Pharmaceuticals (NBY): NovaBay Pharmaceuticals (NBY) has been a stock to watch based on the company's technology and pipeline of products that could provide an alternative to standard antibiotics, given the ongoing dilemma of antibiotic resistance that may be rendering current treatments irrelevant.
Earlier this year NovaBay announced a key strategic partner for the launch of its first commercial product, NeutroPhase, and on Tuesday the company announced another deal with Virbac Animal Health that could put its Aganocide products on the market for veterinary use as well.
According to Tuesday's announcement, "NovaBay will receive an upfront payment plus additional support for research and development. Virbac will conduct veterinary studies using NovaBay's Aganocide compounds in order to assess feasibility for treating several veterinary indications.
Virbac will have the option to license exclusive worldwide rights to market Aganocides for one or more of these indications. If exercised, NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
This year could shape up to be a pivotal one for NovaBay, with a full product launch planned and the continuation and/or initiation of late stage trials that may position the company's Aganocide compounds as the standard of care for the anti-infective markets.
Given that potential, NBY's current market cap may not be fully reflecting the company's pipeline potential.
More to follow regarding NBY from VFC's Stock House.
Disclosure: Long CELH, CVM, AMPE.
Contact VFC's Stock House: email@example.com
Originally published at: http://vfcsstockhouse.com